NanoViricides, Inc. (NYSE American: NNVC) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its clinical-stage antiviral drug NV-387 for the treatment of measles. This designation provides potential incentives including tax credits, fee exemptions, and seven years of market exclusivity upon approval, significantly bolstering the company's regulatory pathway for the drug.
NV-387 is a broad-spectrum antiviral candidate that has demonstrated in vivo activity against measles and is being developed to address the increasing frequency of global measles outbreaks. The Orphan Drug Designation underscores the FDA's recognition of the unmet medical need for effective measles treatments, particularly as vaccination rates wane and outbreaks resurge in various regions. According to the company, NV-387's mechanism of action as a broad-spectrum antiviral makes it a promising candidate not only for measles but also for other viral infections, including respiratory syncytial virus (RSV), COVID-19, influenza, and monkeypox.
NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's lead drug candidate, NV-387, has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is now focused on advancing NV-387 into Phase II human clinical trials. In addition to measles, NV-387 has shown efficacy in animal models for monkeypox, smallpox, and other viruses.
The Orphan Drug Designation is expected to accelerate the development and review process for NV-387, providing the company with additional support from the FDA, including protocol assistance and potential funding for clinical trials. This milestone is critical for NanoViricides as it seeks to bring a novel antiviral therapy to market, especially in the context of rising global health threats from emerging and re-emerging viral diseases.
For more information about NanoViricides and its pipeline, visit the company's newsroom at https://ibn.fm/NNVC. The full press release regarding the Orphan Drug Designation is available at https://ibn.fm/uIWWv.
